Latest News 2002
                                               
 

                                              February  2002            

                                            Click Here for 2001

Back to index

 

                           Community Notice: Procedure to avoid missing doses on the PEG-Intron Access Assurance Program
                           Amarillo Biosciences to Receive Patent on Solid Dosage Forms of Interferon; Company Also Obtains Additional Funding Through Private Placement
                           New Drugs for Treatment of Chronic Hepatitis C
                           Hepatitis Screenings Could Save Money, Lives
                           Study Reports Hepatitis C Impairs Cognitive Functioning: memory, concentration, depression
                           Phlebotomy May Delay Progression of Liver Fibrosis in Chronic Hepatitis C Patients
                           How Green Tea May Fight Inflammation
                           FDA Probes Anti-Anxiety Herb
                           High proportion of untreated chronic hepatitis C patients suffers emotional distress
                           2005-Pegylated form of Infergen
                           How many patients are being treated with  interferon-based antiviral therapies ?

 

 

Community Notice: Procedure to avoid missing doses on the PEG-Intron Access Assurance Program

February 2, 2002

Recently HAAC obtained information from some HCV patients currently on the PEG-Intron Access assurance program not receiving their refill prescriptions in a timely manner, and consequently some were missing scheduled doses. HAAC wrote to the FDA concerning the matter. The agency is in communication with Schering–Plough on the issue.

According to representatives from the FDA, Schering does not acknowledge any awareness of people enrolled in the program missing doses. However Schering did provide the agency with a suggested procedure for patients should they feel they are “in a tight situation with their prescription”.

HAAC is unaware of Schering making any effort to publicize this information such as by contact HCV community advocates about this procedure; so we will. And we ask our fellow community advocates to help by circulating this information on their websites, email lists, etc.

HCV patients who have chosen this treatment with their healthcare providers need to avoid treatment interruptions. According to the company, this program is supposed to do. We will appreciate email feedback from patients who use this procedure. Please let us know if this method is working or not and if you are getting drug in a timely manner or not. We can then inform FDA and Schering of your reports, positive or negative. HAAC will NOT divulge your name or other confidential identifying information without your express permission to do so.

HERE IS WHAT TO DO

1. Patients that are already enrolled in the access program should call the program at 1.888.437.2608 and explain the problem to the live person at the other end. You can access a live person after a couple of presses of the keypad following the directions given. They are available during business hours, which are apparently 9 am - 12 midnight M - F, and 9 - 5 on Saturday, eastern time. The representatives are supposed to be trained to arrange expedited delivery of drug to the patient's pharmacy through established procedures.

2. If patients have problems with the access program, they should then call the Customer Service number at 1.800.222.7579. Trained customer service people are apparently standing by, ready to handle problems, including expedited delivery of drug.

3. This procedure is ONLY for patients who are already receiving treatment on this program. This does NOT affect those patients registered who are currently waitlisted to start treatment due to the shortage of available drug.

Thank you,

Brian Klein, MA, LMSW
HAAC-SF

 

 

Amarillo Biosciences to Receive Patent on Solid Dosage Forms of Interferon; Company Also Obtains Additional Funding Through Private Placement

AMARILLO, Texas, Feb. 5 /PRNewswire-FirstCall/ -- After a 10-week delay caused by the anthrax threat to the U.S. mail in the nation's capital, Amarillo Biosciences, Inc. (OTC Bulletin Board: AMAR - news; ABI), will soon be issued a long-sought patent for its oral formulation of interferon alpha.

``Receipt of this patent is extremely important for us,'' said Dr. Joseph M. Cummins, President and CEO of ABI, which already has a portfolio of 20 issued patents in the medical and pharmaceutical fields. ``Now, no one else will be able to produce a lozenge or tablet with interferon alpha without risk of infringing this patent, which will provide protection for the low dose oral delivery of interferon for 17 years from the date of issue.''

ABI had expected the patent to issue earlier, having received a Notice of an Allowance of Claims from the U.S. Patent & Trademark Office (PTO) last year and having submitted the required issue fee to the PTO on October 30. However, because mail deliveries to Washington, D.C., were held up for decontamination due to the anthrax scare, the issue fee was not received by the PTO until January 10, 2002. Patents typically issue within 2-3 months of payment of the issue fee.

Dr. Cummins also noted another step for the Company, announcing that ABI has received an additional $500,000 in funding through a private placement. One million unregistered common ABI shares were sold at $0.50 per share, netting the Company $450,000 after deducting selling expenses. The funds will supplement license fees and sales receipts of $485,000 received in September and help support ongoing Company operations, sales efforts and research trials in an effort to attain profitability in 2002.

About Amarillo Biosciences, Inc.

Amarillo Biosciences, Inc. is a pioneer in the research of low dose, orally-administered interferon alpha as a treatment for a variety of conditions including Sjogren's syndrome, fibromyalgia syndrome, Behcet's disease, hepatitis B and C, and opportunistic infections in patients who are HIV positive. Additional information is available on the Amarillo Biosciences, Inc. web site at www.amarbio.com .

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon alpha or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see ``Item 1. Description of Business'' of the Company's Form 10-KSB for the year ended December 31, 2000.

SOURCE: Amarillo Biosciences, Inc.

 

 
   
http://www.hivandhepatitis.com/hep_c/news/020802a.html

New Drugs for Treatment of Chronic Hepatitis C

By Mark Nelson, MD

Although recent advances have occurred in the treatment of chronic hepatitis C, new agents with reduced toxicity and increased effectiveness are urgently needed. Researchers presented new data on treatments for hepatitis C from animal models and from early clinical studies at a recent hepatitis conference, Drug Development for Antiretroviral Therapies 2001 (Hep DART 2001), held December 16-20, 2001, in Maui, Hawaii.

Hepatic C protease inhibitors
New analogues of ribavirin
Ribozymes

Editor's Note: unless otherwise indicated, all references are to Drug Development for Antiretroviral Therapies 2001 (Hep DART 2001), held December 16-20, 2001, in Maui, Hawaii.

Hepatic C Protease Inhibitors
[Abstract 018]
Similar to HIV, hepatitis C has a protease which is essential for viral replication. This protease differs from the HIV protease in that it is a serine protease which in hepatitis C has been ascribed to the NSV3 protein in concert with the NSV4 a co-factor. Several agents have been developed with activity against this protease which is a chemotrysin like serine protease with a shallow substrate binding region.
The most likely inhibitor to enter clinical studies in the future is the Boehringer Ingelheim compound 8, which has been tested in cell cultures with an EC50 of between 76 and 440 nanograms depending on the system used. This compound has a low potential for drug interactions having low inhibition of P450, but is heavily protein bound (97.6%). In studies in the rat model, an oral dose has shown a plasma bio-availability of only 5%. Due to the high plasma protein binding the volume of distribution is low.

New Analogues of Ribavirin
[Abstract 019]
Two new analogues of ribavirin were discussed. First of these levovirin is the L enantiomer of ribavirin which has a similar immunomodulatory activity as ribavirin, but without the associated toxicity. This drug has entered a phase I study at doses of between 200 and 1200mg and is well tolerated and orally absorbed.
The other compound viramidine is a prodrug of ribavirin, which is converted to the active drug by adenosine deaminase within the liver. Viramidine itself has no anti-HCV inhibitor but when converted to ribavirin shows similar antiviral activity against DNA and RNA viruses. Within a monkey model a dose of 600mg per kg had no significant hematological toxicity in males although it was associated with 10% reduction in red blood cells in the female. This compares with ribavirin which showed an 11-14% loss of red blood cells in males and 23-25% in females. Calculation showed that the therapeutic index for this drug was 6 times better than for ribavirin.

Ribozymes
[Abstract 020]
Ribozymes are catalytic RNA binders entailing a catalytic core with two binding arms which cleave target sequence allowing cell nucleases to destroy the viral RNA. Two ribozymes, one with activity against hepatitis B and one against hepatitis C were reported. Hep B zyme is targeted against the pregenomic RNA at the 31 terminus of the major transcript of hepatitis B. In cell systems their use led to a reduction in production of HBsAg and HBeAg. In a transgenic mouse model, doses of this ribozyme at between 30 and 300mg gave a viral load reduction of approximately 1.6-2.4 log compared with 3TC giving a reduction of approximately 2 log within this system.
Ribozymes against hepatitis C are associated with significant reduction in HCV RNA production in vitro, and have a synergistic effect with interferon with a dose response effect of the ribozyme. In addition, they allowed a 12% reduction of interferon without loss of efficacy suggesting that this drug is useful in allowing dose reduction of interferon. In the mouse model, delivery by the sub-cutaneous route led to active levels of ribozyme with little toxicity apart from injecting site reactions and basophilia, probably secondary to an accumulation of the ribozyme in renal tubular cells and lymph nodes. A phase I study has commenced with individuals receiving doses of between 3 and 90mg for up to 28 days. So far the drug has been well tolerated with no abnormalities in laboratory parameters and no major patient toxicity.

02/08/02
Full report on new therapies for hepatitis B and C in Selected Highlights from
Drug Development for Antiretroviral Therapies 2001 (Hep DART 2001). December 16-20, 2001. Maui, Hawaii.
 

 

  Hepatitis Screenings Could Save Money, Lives
Sat Feb 9, 3:00 AM ET
By Robert Preidt
HealthScoutNews Reporter

SATURDAY, Feb. 9 (HealthScoutNews) -- Screening middle-age Americans for
hepatitis C could cut medical costs and increase life expectancy for the
people found to have the potentially fatal disease, says new research from
the University of Michigan Health System.

"Most people don't have any signs or symptoms," of hepatitis C, says Dr.
Thomas Shehab, a fellow in the university's gastroenterology division.
"Given that people are asymptomatic and the disease is potentially
affecting their liver without them knowing about it, we have to go looking
for it," Shehab says. It's estimated about 4.5 million Americans are
infected with hepatitis C, yet few know they have the blood-borne virus. It
can go undetected for years and cause cirrhosis, liver failure and liver
cancer.

Shehab and two colleagues used a special mathematical model to estimate the
impact of hepatitis C screening on life expectancy and associated medical
costs in a population of 45-year-old Americans. They found that such a
screening program, which involves a simple blood test, would cost about
$11,000 per life year saved, assuming that a response to therapy led to
long-term medical care. They say that's well below the $50,000 per life
year saving that's considered acceptable in the United States, Shehab says.
The findings were presented at a recent meeting of the American College of
Gastroenterology.

Currently, most doctors just test for hepatitis C when someone shows
symptoms of liver disease, Shehab says.
"Our research has suggested that we're missing the boat, that there are a
ton of people out there walking, talking and feeling well who have the
disease who aren't being diagnosed, either because they're not being asked
about their risk factors or because nobody thinks to test them for the
disease," Shehab says.
There are a number of factors that put you at risk for hepatitis C. They
include receiving a blood transfusion or organ transplant before 1992,
sexual promiscuity, being born to a mother with hepatitis C, or using
intravenous drugs. As for that last risk factor, Shehab notes you don't
have to be a hard-core drug user to be at risk.
"They can be somebody who at one time in their 20s or 30s experimented with
intravenous drugs, and shared a needle," he says.

The need for a widespread screening program for hepatitis C was made
apparent by the terrorist attacks of Sept. 11, Shehab adds. More than
10,000 people who donated blood in the aftermath of those attacks will be
notified they have hepatitis C, says the American Liver Foundation (ALF).
But while hepatitis C is a serious public health issue, a universal
screening program for hepatitis C isn't a priority for the foundation.

"I don't think anybody's ever brought this up before," says Dr. Caroline
Riely, the associate medical director of ALF. She says ALF does advocate
screening for those at special risk, including people who use drugs, who
received blood transfusions before 1992, or who engage in risky sexual
behavior. One major problem with universal hepatitis C screening is
privacy, she adds. "There's a lot of concern about screening large
populations in terms of what it does to your employability, insurance and
that kind of thing. So there would be some potential downsides," Riely says.

What To Do
Riely says hepatitis C kills 8,000 to 10,000 Americans each year. That
number is expected to increase to 20,000 to 30,000 a year within a decade.
There is no vaccine to prevent hepatitis C infection. Antiviral medicines
are effective in only about 2 to 3 of every 10 hepatitis C patients, says
the Centers for Disease Control and Prevention (CDC). If you do have
hepatitis C, you need to determine if you have liver disease and, if so,
what treatments may be required.

You also need to learn how to protect your liver from more harm and how to
prevent spreading hepatitis C to other people, the CDC says.
Protecting your liver includes: not drinking alcohol; visiting your doctor
regularly; and not taking any medications -- including over-the-counter or
herbal products -- without consulting your doctor.
Hepatitis C patients shouldn't donate blood, organs, other tissues or
sperm. They shouldn't share a toothbrush, razor or other personal care
items that may have blood on them. Any cuts or sores on the skin should be
covered.
For more information about hepatitis C, go to the CDC, HepNet or the
National Hepatitis C Coalition.

Source URL:
http://story.news.yahoo.com/news?tmpl=story&u=/hsn/20020209/hl_hsn/hep

 

 

 
New HCV Drug in Phase I
Idun Pharmaceuticals' Clinical Trial Demonstrates Safety Of Liver Disease Drug
- Phase I Trial Demonstrates Safety and Opens the Door To Treat Multiple Liver Diseases -
 
 
 
  SAN DIEGO, Jan. 31 /PRNewswire/ -- Idun Pharmaceuticals, Inc. today announced the results of its Phase 1 clinical trial of IDN-6556. The drug was safe and well tolerated in a clinical study involving 50 normal adults. Evaluation of patients with mild hepatic impairment is ongoing. In the Phase 1 study, IDN-6556 was administered in both single doses and for a week of therapy with various doses. The drug was well tolerated in all groups of subjects.
 
"We are excited to have completed this Phase 1 stage of the drug's development," said Dr. David Shapiro, Chief Medical Officer and Executive Vice President at Idun. "This drug may prove to be useful in multiple liver diseases and we will shortly start Phase 2 studies to evaluate its effects on different groups of hepatic patients. We will conduct Phase 2 trials of individuals with hepatitis C virus (HCV) infections, alcoholic liver disease and, subsequently, additional trials of individuals experiencing acute alcoholic hepatitis. HCV affects about 4 million Americans and another 200 million people worldwide. Acute alcoholic hepatitis is an often-lethal condition that affects about 85,000 people in the U.S. alone and for which there is no effective treatment. We believe that IDN-6556 can play an important role in the standard care for people with HCV, acute alcoholic hepatitis, and many other liver diseases."
 
"There are literally more than a half-billion people in the world suffering with liver diseases that may benefit from this drug," added Dr. Steve Mento, Idun's President and CEO. "The success of the Phase 1 trial of our caspase inhibitor is the first clinical step to a new and important therapy for patients with liver disease. It also validates Idun's approach to small molecule drug development and the role that apoptosis modulators can play in the treatment of a number of diseases. We've always believed that caspase inhibitors would be effective drugs for a number of diseases. IDN-6556 is the first broad-spectrum caspase inhibitor to be studied in humans.
 
"This is just the beginning of many exciting new opportunities that can come from Idun's technology. We have programs in earlier stages of development in cardiovascular disease, inflammation, central nervous system diseases, and cancer with just as much potential."
 
Idun Pharmaceuticals, Inc. is a biopharmaceutical company located in San Diego, CA, creating innovative human therapeutics with a primary focus on controlling apoptosis, or programmed cell death. Apoptosis is a genetically controlled normal physiological process mediated by a cascade of intra-cellular proteins. Too much, inappropriate, or too little apoptosis is believed to play a role in many important human diseases. Idun believes that controlling the cell death process will have utility in treating cancer, neurodegenerative diseases, ischemic disorders and cardiovascular disease. The company has adopted a commercialization strategy encompassing strategic collaborations with major pharmaceutical companies; internal, independent development of selected small molecule therapeutics; and out-licensing of diagnostics, gene therapies, and bioproduction technologies. Idun has an extensive patent portfolio covering the fundamental and core technologies involved in the regulation of cell death and has established partnerships with Abbott Laboratories in cancer, with Elan Corporation, plc in stroke, and Becton Dickinson and Company in research reagents.
 
Some of the statements in this press release are forward-looking statements and do not guarantee future performance and involve risks and uncertainties. Actual results may differ substantially from the results that the forward-looking statements suggest for various reasons. These forward- looking statements are made only as of the date of this press release.
 
SOURCE Idun Pharmaceuticals, Inc.
 
 
Study Reports Hepatitis C Impairs Cognitive Functioning: memory, concentration, depression
 
 
 
  This article is published in the current issue of the journal called Hepatology. The authors report their findings from a small preliminary study. They recommend further study is needed to confirm their findings. These authors report patients in their HCV clinic who have HCV appear to have cognitive impairment and more fatigue, depression, less concentration ability, and less memory ability. The authors caution this is a small preliminary study. They also caution that study bias is possible because these patients were referred to the HCV clinic and so they may not represent all patients such as those not referred to the clinic. Clinic referrals may be sicker. The authors suggest two possible explanations for these symptoms: (1) HCV may directly infect the brain similarly to the way HIV infects the brain, (2) HCV may stimulate the immune system in a way that dysregulates cytokine functioning causing these cytokines to be able to enter the brain and cause dysregulation; this is discussed further near the end of the article. These study findings are consistent with reports from some patients with HCV, that they experience fatigue, anger, hostility, anxiety and depression, and that they feel its associated with having HCV. But, this association has not been well studied. This study was first reported at liver meetings two years ago. In addition other studies have reported similar findings. Here are a few links to these studies, and related articles:
 
Assessment of Fatigue and Psychologic Disturbances in Patients with Hepatitis C Virus Infection
www.natap.org/2001/jul/assessment070901.htm
 
HCV and Brain Dysfunction (report of this study at liver conference 2 years ago)
www.natap.org/2000/ddw/rpt_11.htm
 
HCV and Fatigue
www.natap.org/1999/aug/hcvandfatique82399.html
 
Abstract: Patients with chronic hepatitis C virus (HCV) infection frequently report fatigue, lassitude, depression, and a perceived inability to function effectively. Several studies have shown that patients exhibit low quality-of-l ife scores that are independent of disease severity. We therefore considered whether HCV infection has a direct effect on the central nervous system, resulting in cognitive and cerebral metabolite abnormalities. Twenty-seven viremic patients (HCV+) with biopsy-proven mild hepatitis due to HCV and 16 patients with cleared HCV were tested with a computer-based cognitive assessment battery and also completed depression, fatigue, and quality-of-life questionnaires. The HCV-infected patients were impaired on more cognitive tasks than the HCV-cleared group (mean [SD]: HCV-infected, 2.15 [1.56]; HCV-cleared, 1.06 [1.24]; P = .02). A factor analysis showed impairments in power of concentration and speed of working memory, independent of a history of intravenous drug usage (IVDU), depression, fatigue, or symptom severity. A subgroup of 17 HCV-infected patients also underwent cerebral proton magnetic resonance spectroscopy (1H MRS). The choline/creatine ratio was elevated in the basal ganglia and white matter in this group. Patients who were impaired on 2 or more tasks in the battery had a higher mean choline/creatine ratio compared with the unimpaired patients. In conclusion, these preliminary results demonstrate cognitive impairment that is unaccounted for by depression, fatigue, or a history of IVDU in patients with histologically mild HCV infection. The findings on MRS suggest that a biological cause underlies this abnormality. (HEPATOLOGY 2002;35:433-439.)
 
The HCV-infected group scored significantly worse on the power of concentration (P = .001) and on the speed of memory processes (P = .001) factor scores than the healthy controls.
 
With respect to the affective scores, the HCV-infected group scored worse on the Hospital Anxiety and Depression Scales.
 
There were no statistically significant differences in the subjects' assessment of fatigue in either the physical or mental domains, although there was a trend toward increased fatigue in the HCV-infected group. Similarly, with respect to the SF-36 quality-of-life scale, there were no differences between the 2 groups in the mental summary score. However, there was a significant difference in the physical summary score (P = .006), with lower ratings in the HCV-infected group.
 
Comments By Study Authors
 
These preliminary findings are consistent with cognitive and cerebral 1H MRS metabolite abnormalities in patients with histologically defined mild hepatitis due to HCV infection. The data support the clinical impression and assertions of many HCV-infected patients that they are cognitively impaired ("brain fog"). However, the mechanism underlying these findings remains to be defined.
 
The HCV-infected patients were found to be more depressed than the HCV-cleared group, as has been previously reported. There were no statistically significant correlations between the cognitive factor scores that were abnormal in the HCV-infected group and the depression scores, indicating that impairment on these tasks is unlikely to be secondary to depression. Furthermore, if depression was the sole explanation for cognitive impairment in the HCV-infected patients, it is unlikely that it would cause the selective cognitive impairments that we report.
 
A number of explanations may account for or contribute to the cognitive dysfunction observed in HCV-infected patients, including (1) a biological effect of HCV infection on the central nervous system, (2) the effect of personality or HCV acquisition-associated factors such as a history of IVDU, (3) the effect of affective disorders such as depression, or (4) the effect of subjectively experienced symptoms such as fatigue. It should be noted that these explanations are not necessarily mutually exclusive and might interact.
 
Patients with significant fibrosis or cirrhosis were excluded from the study, thereby excluding minimal hepatic encephalopathy as the cause of the abnormalities.
 
A history of serious drug usage that had stopped at least 2 years before participation in the study (and in most cases much earlier) did not have an impact on cognitive performance, regardless of HCV status.
 
The factor score analysis suggests that concentration and working memory processes may be preferentially impaired. These scores are derived from the summation of the reaction times on various tasks. We considered that the abnormalities might simply be a reflection of pure motor slowing as a result of a peripheral neuromuscular abnormality, but there were no differences in the simple reaction time between the 2 groups indicating impairment of central cognitive processes. Similar findings of slowed processing speed and impaired working memory are the most prominent features of cognitive dysfunction in patients with chronic fatigue syndrome. Such findings have also been reported in the medically asymptomatic stages of HIV infection and are consistent with the involvement of subcortical or frontostriatal brain systems.
 
Although every attempt was made to prevent selection bias in this study, we accept that the study populations may not be wholly representative of the HCV-infected population because they were drawn from a tertiary referral HCV clinic. In particular, it is possible that patients with worse symptoms, both physical and psychological, are more likely to attend the clinic. Conversely, the exclusion of patients who were taking antidepressants, comprising 20% of the initial recruits and possibly those HCV-infected patients who were most likely to have cognitive dysfunction, may have led to an underestimation of the level of cognitive impairment. The purpose of this study was to investigate whether cognitive dysfunction is a feature of HCV infection, whereas larger studies will be required to estimate the prevalence.
 
What may be the cause?
 
Using 1H MRS, the authors reported finding an increase in the basal ganglia and whitematter choline/creatine ratio in patients with chronic HCV infection.
 
Similar metabolite abnormalities in the same spatial distribution as those reported here have been extensively documented in cerebral HIV infection, both in neurosymptomatic and neuroasymptomatic individuals. In the case of HIV, infection of cerebral microglia, possibly via infected monocytes entering the brain, and subsequent microglial activation are believed to underlie the MRS changes. This raises the prospect that the metabolite abnormalities reported in this study are due to direct infection of the brain by HCV. The concept of extrahepatic replication of HCV is not novel, with several lines of evidence suggesting that peripheral blood mononuclear cells are infected. Microglia comprise up to 20% of all glial cells and are developmentally derived from bone marrow precursors of monocytic lineage. It is believed that resident microglia turn over slowly and are replaced by circulating monocytes. It is therefore possible that HCV may be introduced to the central nervous system via infected monocytes, through a "trojan horse" mechanism.
 
An alternative explanation for our findings is a centrally mediated effect of peripherally derived cytokines that may cross the blood-brain barrier. Although cytokines are large peptides, animal studies have demonstrated passage of cytokines including tumor necrosis factor , interferons alfa and gamma, and interleukins (IL) 1 and 1 across the blood-brain and blood-spinal cord barriers. Alternatively, peripherally derived cytokines may bind to the cerebral vascular endothelium, inducing the generation of secondary messengers. Intracerebral cytokines have been associated with immunologic, neurochemical, neuroendocrine, and behavioral activities. Indeed, treatment with interferon alfa is associated with a constellation of symptoms, including depression and reports of memory impairment and cognitive slowing. Whether elevated endogenous cytokines in chronic inflammatory and infective conditions exert a significant cognitive effect is unclear. Several studies have reported elevated levels of circulating cytokines, including IL-1, IL-2, IL-4, IL-6, IL-10, and tumor necrosis factor, in chronic HCV infection; however, a recent study found no correlation between levels of circulating IL-1, IL-6, tumor necrosis factor, and fatigue in chronic HCV infection.
 
 
 

Phlebotomy May Delay Progression of Liver Fibrosis in Chronic Hepatitis C Patients

NEW YORK (Reuters Health) Feb 06 - The use of phlebotomy to reduce iron levels in patients with chronic hepatitis C appears to delay the progression of liver fibrosis, according to a recent report by Japanese investigators. The accumulation of iron in the liver that is observed in patients with chronic hepatitis C has been associated with elevated serum aminotransferase (ALT) levels and liver fibrosis. Although phlebotomy to reduce iron levels in these patients leads to decreased serum ALT, it is unclear if phlebotomy produces long-term beneficial effects.

Dr. Motoyoshi Yano, from Nagoya University, and colleagues assessed the outcomes of 25 chronic hepatitis C patients who underwent phlebotomy to achieve and maintain iron levels of 10 ng/mL or less over a 5-year period. Thirteen additional patients who were virologic nonresponders to interferon therapy alone and had underwent liver biopsies served as a histologic control group.

The initial phlebotomy session produced a significant reduction in serum ALT levels and these levels were maintained with subsequent sessions (p < 0.05), the investigators note in the January issue of The American Journal of Gastroenterology.

At 5-year follow-up, histologic grading scores had improved significantly in the phlebotomy group, but were unchanged in the control group (p < 0.05). Staging scores worsened in the control group, but remained stable in the phlebotomy group (p < 0.005). Furthermore, disease progression was significantly slower in the phlebotomy group (p < 0.05). The current findings suggest that "maintenance of the iron-deficient state has beneficial effects in preventing disease progression in chronic hepatitis C patients," the authors state. Such therapy may be particularly useful in patients with elevated viral levels despite treatment with interferon alone or in combination with ribavirin. However, a prospective controlled study is needed to confirm the present results.

Am J Gastroenterol 2002;97:133-137.

 

 

How Green Tea May Fight Inflammation

By Jacqueline Stenson

SAN DIEGO (Reuters Health) - Studies have suggested that green tea has anti-inflammatory properties and new research may help explain why.

Previous animal studies and other laboratory research have found that chemicals in green tea known as polyphenols act as anti-inflammatory agents, but the mechanism behind this action was not well understood.

Now, Ohio researchers have found that one type of polyphenol known as epigallocatechin-3-gallate, or EGCG, inhibits the expression of the interleukin-8 gene--a key gene involved in the inflammatory response.

``We found that this compound reduced the expression of this gene significantly in a culture cell model,'' said study author Dr. Hector Wong of Cincinnati Children's Hospital Medical Center in Ohio.

``As we increased the dose, the effect was more profound,'' he told Reuters Health.

In a laboratory study presented here Sunday at a meeting of the Society of Critical Care Medicine, the researchers looked at human lung cells that were cultured in a lab dish and treated with a protein called tumor necrosis factor, which typically triggers the expression of IL-8, resulting in the production of the IL-8 protein. In the body, the IL-8 protein attracts white blood cells to a particular site, resulting in tissue inflammation, Wong said.

But when the investigators introduced EGCG in their experiment, they found that it blocked the expression of IL-8. The higher the dose, the greater the effect.

``This compound can short circuit this cascade that leads to inflammation,'' Wong said. It's too soon to advocate drinking cup after cup of green tea in the hopes of treating inflammation, but the results are encouraging and deserve further study, Wong noted.

Reports from Asian populations suggest that green tea consumption may be associated with improvements in various diseases characterized by inflammation, such as colitis and arthritis, he noted. Green tea is also thought to play a role in fighting cancer and heart disease.


 
FDA Probes Anti-Anxiety Herb
February 12, 2002

WASHINGTON (AP) - The 45-year-old woman became jaundiced and then, in just months, became so ill she needed a liver transplant. Her doctor suspects the popular herbal supplement kava.

European health officials report 25 similar cases of liver toxicity, and some countries are barring kava sales. Now the Food and Drug Administration is investigating whether the herbal sedative - promoted to relieve anxiety, stress and insomnia - poses a danger.

Under review are 38 Americans, including the transplant recipient, with medical problems possibly associated with kava use. FDA scientists cannot yet say if the blockbuster seller is to blame.

"The jury's still out on kava," agrees Mark Blumenthal of the American Botanical Council, which joined industry groups in hiring a toxicologist to investigate.

Already Canada has urged consumers not to take kava until the question of its safety is settled; sales have halted in Switzerland and are suspended in Britain; Germany is acting to make kava a prescription drug. Here, the National Institutes of Health has suspended two kava studies.

And the FDA's inquiry has made some startling findings on how Americans use largely unregulated supplements. FDA records show that:

-Two 13-year-olds had to be hospitalized after using kava, one when the sleep-inducing herb apparently interacted with an anesthetic her dentist used on her and the other whose doctor reported she took a deliberate overdose.

-A woman suffering kidney and liver problems used more than 20 supplements and other over-the-counter remedies, handfuls of pills a day.

-Another woman popped up to 15 kava pills every day, more than three times the maximum recommended dose, in addition to Prozac and other prescription drugs.

Aside from the difficulty of teasing out kava's role, no one knows how dangerous it is to mix all these pills willy-nilly and take such high doses, says FDA dietary supplement chief Dr. Christine Taylor.

Worse, "kids who are still developing - their use of this is of particular concern. They're vulnerable," she warns.

It's the latest bad news for the $16 billion supplement industry, which reports sharp sales declines last year. Since summer, the FDA has issued repeated warnings about supplements tainted with drugs and chemicals illegally posing as supplements and asked makers of the liver-damaging herb comfrey to stop selling it for internal use.

Under federal law, no one has to prove dietary supplements are safe or work as advertised before they begin selling. The FDA's $9 million supplement division instead investigates problems and tries to curb use of products it can prove dangerous.

While kava is sold as a natural alternative to prescription anxiety relievers, little is known about how it works, says Dr. Jonathan Davidson of Duke University, who hopes his NIH-suspended study will resume to answer those questions.

No serious side effects arose in studies where people took only kava for short periods, he says, but "the core of the problem is we really don't know very much about the way kava interacts with other medicines."

Kava, a member of the pepper family, has long been used as a ceremonial drink in the South Pacific. Used sporadically, its biggest danger seemed to be if people drank too much of the sedative before driving.

Then, about two years ago, kava in pill form suddenly boomed, bringing in about $30 million in sales, and Europe reported liver damage.

Many of the European patients already had some liver damage before using kava or used alcohol or other known liver-harming substances in addition to the herb, Blumenthal cautions. That suggests if kava is risky, it might be only to certain people.

Also unclear is why there are fewer reports of kava-linked serious liver injury in the in the United States - a handful so far - than in Europe. Taylor wonders if different herbal cultivars are sold here but says the difference could be merely that unlike European doctors, U.S. physicians are not required to report suspicious medical problems to the government.

While scientists sort out the scare, what should kava users do? The consumer advocacy Center for Science in the Public Interest wants the FDA to urge Americans to talk with a doctor before using kava.

Even Blumenthal's pro-herb group advises caution. He says people should avoid kava if they have liver problems, regularly consume alcohol or take liver-affecting drugs; should not take the supplement for more than a month without a doctor's advice; and should discontinue use if symptoms of jaundice appear, such as yellowing of the eyes.

 

.  

High proportion of untreated chronic hepatitis C patients suffers emotional distress

Approximately 35% of patients with chronic hepatitis C, who are not receiving antiviral therapy, suffer from clinically significant emotional distress, claim researchers from Ann Arbor, Michigan, USA. 
 
The team determined the prevalence, type, and severity of emotional distress in a large group of consecutive chronic hepatitis C (CHC) patients not receiving antiviral therapy. 
 
They reported their results in the March issue of the Journal of Hepatology. 
 
A brief symptom inventory, together with a questionnaire, was used to study 220 outpatients with compensated CHC. 
 
Of the participants, 35% reported significantly elevated global severity index (GSI) T-scores, compared to an expected frequency of 10% in population controls.  
 
In addition, significantly elevated depression, anxiety, somatization, psychoticism, and obsessive-compulsive subscale T-scores were reported in 28-40% of subjects. 
 
Subjects with an active psychiatric co-morbidity had significantly higher GSI and subscale T-scores, compared to subjects with active medical co-morbidities and subjects without medical or psychiatric co-morbidities. 
 
However, patients with CHC alone were also found to have a higher frequency of elevated GSI T-scores compared to population controls (20% versus 10%). 
 
Robert J. Fontana, of the University of Michigan Medical School, Ann Arbor, said on behalf of his colleagues, "Clinically significant emotional distress was reported in 35% of chronic hepatitis C patients not receiving antiviral therapy. 
 
"In addition to depression, a broad array of psychological symptoms was observed." 
"Further investigation into the etiopathogenesis and treatment of emotional distress in chronic hepatitis C patients is warranted," he concluded. 
 
J Hepatol 2002; 36(3): 401-7
22 February 2002  
 
http://www.gastrohep.com/news/news.asp?id=1133
 

 
http://www.infergen.com/indexa.html .

2005-Pegylated form of Infergen

About InterMune

InterMune is a commercially driven biopharmaceutical company focused on the commercialization, development and applied research of life-saving therapies for pulmonary disease, infectious disease and cancer. For additional information about InterMune, please visit www.intermune.com.

Except for the historical information contained herein, this press release contains certain forward-looking statements that involve risks and uncertainties, including without limitation statements indicating that:
the Company anticipates that the continued unmet medical need for effective advanced hepatitis C infection treatments will be a key driver of the near-term revenue growth of Infergen;
and that the Company is developing a pegylated form of Infergen that the Company believes has the potential to capture a significant portion of the maximum $3 billion U.S. market opportunity for hepatitis C infections once that product becomes available in 2005. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to those discussed in detail under the heading "Risk Factors" and the other risks and factors discussed in InterMune's 8-K report filed with the SEC on December 21, 2001, and other periodic reports (i.e., 10-K, 10-KA, 10-Q and 8-K) filed with the SEC, which are incorporated herein by reference. The risks and other factors that follow, concerning the forward-looking statements in this press release, should be considered only in connection with the fully discussed risks and other factors discussed in detail in the 8-K report and InterMune's other periodic reports filed with the SEC. Although currently there is an unmet medical need for effective advanced HCV treatments, the launch of pegylated products into this market by Schering Plough and Roche may inhibit the near-term revenue growth of Infergen. InterMune's establishment of a pegylated form of interferon alfacon-1 for the treatment of hepatitis C infections by 2005 is subject to the uncertainties and risks of significant clinical development, regulatory, supply, intellectual property and competitive barriers to entry. InterMune's projection concerning the maximum $3 billion market opportunity for Infergen is subject to the risks and uncertainties that it may prove to be high if: only a subset of patients respond to therapy, the actual dosage is different than currently anticipated, the treatment regimen is different than currently anticipated, InterMune cannot sell the drug at the price that is currently anticipated or a competitor's drug is more effective or costs less than InterMune's


 

How many patients are being treated with  interferon-based antiviral therapies ?

Surprisingly small effect of antiviral treatment in patients with hepatitis C

The majority of patients with hepatitis C virus infection are not
candidates for interferon-based antiviral therapies, finds a study
published in the latest issue of the Annals of Internal Medicine.

A team from Cleveland, Ohio, USA, determined the applicability and
usefulness of interferon-based antiviral therapy in a metropolitan clinic
population of persons with hepatitis C virus (HCV) infection.

A total of 327 patients, referred to the liver clinic after a positive
result for antibody against HCV on enzyme-linked immunosorbent assay, were
included in the study.

Treatment rates, and reasons for non-treatment, were noted.

Some 34 patients had no detectable HCV RNA.

Only 23% of patients with HCV were treated with antiviral therapy.
Annals of Internal Medicine

Of the remaining 293 patients, 72% were not treated for several reasons.

The reasons were as follows: 37% did not adhere to evaluation procedures,
34% had medical or psychiatric contraindications, and 13% had ongoing
substance or alcohol abuse.

In addition, 11% preferred no treatment, and 5% had normal liver enzyme
levels.

Only 83 patients (28%) were treated. The researchers found that, of these,
13% had a sustained viral response.

Dr Yngve Falck-Ytter, of the MetroHealth Medical Center and Case Western
Reserve University, Cleveland, concluded on behalf of fellow authors, "Most
patients with HCV infection are not candidates for interferon-based therapies.

"Alternative interventions should be sought for these patients."

Ann Intern Med 2002; 136: 288-92
20 February 2002
 

 
 
   
   
Reviewed Feb 2004
HOME Liver Cancer
FAQ Great Place To Start Autoimmune Hepatitis
Have You Just Been Diagnosed ? Other Medical Conditions & HCV
Glossary HCV Worldwide News & Research
History Of HCV HCV News Archives 2001-2002
Your Liver Functions Internet Conference Reports on All New and Current HCV Therapies
Symptoms Of HCV Nutrition & HCV
Transmission Of HCV Interviews: Members & Professionals
Sex And HCV HCV Support Groups Listed By State
Understanding Your Blood Tests  Labs Transplant Support Groups Listed By State
Monitoring Blood Work On Treatment Insurance, Financial Aid & Free Meds
Liver Biopsy Understanding Your Results How to Find a Doctor & What to Ask
Viral Loads Members Share Their First Shot Experience
Genotypes Shared Stories From Our  Members
Infergen Your Questions & HCV
 Inhibitors &  New Therapies Chat Room & Message Boards
Peg Intron & Pegasys Books On HCV
Help With Side Effects During Treatment Food For The Soul Inspirational Stories
Drug Interactions & Treatment Informative Links
Latest HCV Trials Pictures Of Our Members
Liver Fibrosis What's New at Janis and Friends
Cirrhosis Sign Our Guestbook
Transplants Contact Us mailto:JansDream@angelhaven.com
Current Transplant Research In Memory Of Janis